Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Decreased serum levels of the inflammaging marker miR-146a are associated with clinical response to tocilizumab in COVID-19 patients

View ORCID ProfileJacopo Sabbatinelli, View ORCID ProfileAngelica Giuliani, View ORCID ProfileGiulia Matacchione, View ORCID ProfileSilvia Latini, View ORCID ProfileNoemi Laprovitera, View ORCID ProfileGiovanni Pomponio, Alessia Ferrarini, View ORCID ProfileSilvia Svegliati Baroni, Marianna Pavani, Marco Moretti, View ORCID ProfileArmando Gabrielli, View ORCID ProfileAntonio Domenico Procopio, View ORCID ProfileManuela Ferracin, View ORCID ProfileMassimiliano Bonafè, View ORCID ProfileFabiola Olivieri
doi: https://doi.org/10.1101/2020.07.11.20151365
Jacopo Sabbatinelli
1Department of Clinical and Molecular Sciences, Università Politecnica delle Marche, Ancona, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jacopo Sabbatinelli
Angelica Giuliani
1Department of Clinical and Molecular Sciences, Università Politecnica delle Marche, Ancona, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Angelica Giuliani
Giulia Matacchione
1Department of Clinical and Molecular Sciences, Università Politecnica delle Marche, Ancona, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Giulia Matacchione
Silvia Latini
1Department of Clinical and Molecular Sciences, Università Politecnica delle Marche, Ancona, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Silvia Latini
Noemi Laprovitera
2Department of Experimental, Diagnostic, and Specialty Medicine (DIMES), University of Bologna, Bologna, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Noemi Laprovitera
Giovanni Pomponio
3Clinica Medica, Department of Internal Medicine, Ospedali Riuniti, Ancona, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Giovanni Pomponio
Alessia Ferrarini
3Clinica Medica, Department of Internal Medicine, Ospedali Riuniti, Ancona, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Silvia Svegliati Baroni
1Department of Clinical and Molecular Sciences, Università Politecnica delle Marche, Ancona, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Silvia Svegliati Baroni
Marianna Pavani
1Department of Clinical and Molecular Sciences, Università Politecnica delle Marche, Ancona, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marco Moretti
4Laboratory Medicine, Ospedali Riuniti, Ancona, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Armando Gabrielli
1Department of Clinical and Molecular Sciences, Università Politecnica delle Marche, Ancona, Italy
3Clinica Medica, Department of Internal Medicine, Ospedali Riuniti, Ancona, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Armando Gabrielli
Antonio Domenico Procopio
1Department of Clinical and Molecular Sciences, Università Politecnica delle Marche, Ancona, Italy
5Center of Clinical Pathology and Innovative Therapy, IRCCS INRCA, Ancona, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Antonio Domenico Procopio
Manuela Ferracin
2Department of Experimental, Diagnostic, and Specialty Medicine (DIMES), University of Bologna, Bologna, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Manuela Ferracin
  • For correspondence: f.olivieri@univpm.it massimiliano.bonafe@unibo.it manuela.ferracin@unibo.it
Massimiliano Bonafè
2Department of Experimental, Diagnostic, and Specialty Medicine (DIMES), University of Bologna, Bologna, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Massimiliano Bonafè
  • For correspondence: f.olivieri@univpm.it massimiliano.bonafe@unibo.it manuela.ferracin@unibo.it
Fabiola Olivieri
1Department of Clinical and Molecular Sciences, Università Politecnica delle Marche, Ancona, Italy
5Center of Clinical Pathology and Innovative Therapy, IRCCS INRCA, Ancona, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Fabiola Olivieri
  • For correspondence: f.olivieri@univpm.it massimiliano.bonafe@unibo.it manuela.ferracin@unibo.it
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Current COVID-19 pandemic poses an unprecedented threat to global health and healthcare systems. The most amount of the death toll is accounted by old people affected by age-related diseases that develop a hyper-inflammatory syndrome. In this regard, we hypothesized that COVID-19 severity may be linked to inflammaging. Here, we examined 30 serum samples from patients enrolled in the clinical trial NCT04315480 assessing the clinical response to a single-dose intravenous infusion of the anti-IL-6 receptor drug Tocilizumab (TCZ) in COVID-19 patients with multifocal interstitial pneumonia.

In these serum samples, as well as in 29 age- and gender-matched healthy control subjects, we assessed a set of microRNAs that regulate inflammaging, i.e. miR-146a-5p, miR-21-5p, and miR-126-3p, which were quantified by RT-PCR and Droplet Digital PCR.

We showed that COVID-19 patients who did not respond to TCZ have lower serum levels of miR-146a-5p after the treatment (p=0.007). Among non-responders, those with the lowest serum levels of miR-146a-5p experienced the most adverse outcome (p=0.008). Our data show that a blood-based biomarker, such as miR-146a-5p, can provide clues about the molecular link between inflammaging and COVID-19 clinical course, thus allowing to better understand the use of biologic drug armory against this worldwide health threat.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

NCT04315480

Funding Statement

This study was supported by grants from Universita' Politecnica delle Marche (RSA grant to FO and ADP) and Italian Ministry of Health ('Ricerca corrente' grant to IRCCS INRCA). MF lab is supported by Italian Association for Cancer Research (AIRC) and Pallotti Fund. MB is supported by Pallotti Fund.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was approved by the Regional Institutional Review Board (Comitato Etico Regione Marche).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The data that support the findings of this study are available from the corresponding authors upon reasonable request.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted November 21, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Decreased serum levels of the inflammaging marker miR-146a are associated with clinical response to tocilizumab in COVID-19 patients
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Decreased serum levels of the inflammaging marker miR-146a are associated with clinical response to tocilizumab in COVID-19 patients
Jacopo Sabbatinelli, Angelica Giuliani, Giulia Matacchione, Silvia Latini, Noemi Laprovitera, Giovanni Pomponio, Alessia Ferrarini, Silvia Svegliati Baroni, Marianna Pavani, Marco Moretti, Armando Gabrielli, Antonio Domenico Procopio, Manuela Ferracin, Massimiliano Bonafè, Fabiola Olivieri
medRxiv 2020.07.11.20151365; doi: https://doi.org/10.1101/2020.07.11.20151365
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Decreased serum levels of the inflammaging marker miR-146a are associated with clinical response to tocilizumab in COVID-19 patients
Jacopo Sabbatinelli, Angelica Giuliani, Giulia Matacchione, Silvia Latini, Noemi Laprovitera, Giovanni Pomponio, Alessia Ferrarini, Silvia Svegliati Baroni, Marianna Pavani, Marco Moretti, Armando Gabrielli, Antonio Domenico Procopio, Manuela Ferracin, Massimiliano Bonafè, Fabiola Olivieri
medRxiv 2020.07.11.20151365; doi: https://doi.org/10.1101/2020.07.11.20151365

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (62)
  • Allergy and Immunology (144)
  • Anesthesia (47)
  • Cardiovascular Medicine (419)
  • Dentistry and Oral Medicine (74)
  • Dermatology (49)
  • Emergency Medicine (148)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (176)
  • Epidemiology (4908)
  • Forensic Medicine (3)
  • Gastroenterology (185)
  • Genetic and Genomic Medicine (690)
  • Geriatric Medicine (72)
  • Health Economics (193)
  • Health Informatics (636)
  • Health Policy (325)
  • Health Systems and Quality Improvement (209)
  • Hematology (87)
  • HIV/AIDS (157)
  • Infectious Diseases (except HIV/AIDS) (5414)
  • Intensive Care and Critical Care Medicine (334)
  • Medical Education (96)
  • Medical Ethics (24)
  • Nephrology (77)
  • Neurology (692)
  • Nursing (42)
  • Nutrition (115)
  • Obstetrics and Gynecology (130)
  • Occupational and Environmental Health (211)
  • Oncology (447)
  • Ophthalmology (140)
  • Orthopedics (36)
  • Otolaryngology (91)
  • Pain Medicine (37)
  • Palliative Medicine (18)
  • Pathology (131)
  • Pediatrics (203)
  • Pharmacology and Therapeutics (131)
  • Primary Care Research (88)
  • Psychiatry and Clinical Psychology (788)
  • Public and Global Health (1833)
  • Radiology and Imaging (328)
  • Rehabilitation Medicine and Physical Therapy (142)
  • Respiratory Medicine (258)
  • Rheumatology (88)
  • Sexual and Reproductive Health (69)
  • Sports Medicine (63)
  • Surgery (102)
  • Toxicology (23)
  • Transplantation (29)
  • Urology (39)